![Preston Noon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Preston Noon
Directeur/Membre du Conseil chez ViTToria Biotherapeutics, Inc.
Postes actifs de Preston Noon
Sociétés | Poste | Début | Fin |
---|---|---|---|
Agent Capital LLC
![]() Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Private Equity Investor | - | - |
ViTToria Biotherapeutics, Inc.
![]() ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Preston Noon
Formation de Preston Noon
University of Connecticut | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 4 |
Opérationnelle
Private Equity Investor | 1 |
Masters Business Admin | 1 |
Director/Board Member | 1 |
Sectorielle
Finance | 2 |
Consumer Services | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Agent Capital LLC
![]() Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Finance |
ViTToria Biotherapeutics, Inc.
![]() ViTToria Biotherapeutics, Inc. BiotechnologyHealth Technology viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Preston Noon
- Expérience